Richard Kardell, DO
Otolaryngology · Berlin, NHNPI 1649338468
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $987 of the $1,175 with a category attached, or 84.0%. It is spread thinly across 9 manufacturers, the largest accounting for just 24.0% — the pattern of someone who eats at a lot of different presentations.
Across 44 payments — averaging $26.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$282
- GSK$281
- Sanofi-aventis U.S. LLC$211
- Regeneron Healthcare Solutions, Inc.$138
- Sanofi$94
- Merz North America, Inc.$75
- plus $95 from 3 others
What the payments were for
- Food & beverage$98784%
- Education$18816%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $282 |
| GSK | 12 | $281 |
| Sanofi-aventis U.S. LLC | 3 | $211 |
| Regeneron Healthcare Solutions, Inc. | 5 | $138 |
| Sanofi | 5 | $94 |
| Merz North America, Inc. | 3 | $75 |
| Genentech USA, Inc. | 2 | $46 |
| Novartis | 2 | $32 |
| Olympus America Inc. | 1 | $17 |
How this compares
$1,175 in reported general payments places this provider in the 70th percentile of 44 otolaryngology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 18 | $74,756 |
| Epinephrine | 14 | $1,529 |
| Ofloxacin | 11 | $889 |
| Ipratropium Bromide | 19 | $550 |
| Doxycycline Hyclate | 18 | $397 |
| Fluticasone Propionate | 18 | $309 |
| Omeprazole | 22 | $226 |
| Montelukast Sodium | 14 | $61 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in Berlin
- James BartelsManchester$5K
- Joseph PaydarfarLebanon$5K
- Michael ToscanoDover$4K
- Taraneh AzarPortsmouth$4K
- Christopher KnoxRochester$3K
- Avery NelsonKeene$2K
- Keith JorgensenDerry$2K
- Ross JohnstonLebanon$2K
- Carly SchrageLaconia$2K
- Angela DamianoKeene$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.